Drug Profile
Adagloxad simolenin - OBI Pharma
Alternative Names: Adagloxad simolenin; Cancer vaccine Globo-H; Globo H-KLH; Globo-H vaccine; OBI-822; OBI-822/OBI-821; OPT-22; OPT-822/821; OPT-822/OPT-821Latest Information Update: 05 Oct 2023
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; OBI Pharma
- Class Antineoplastics; Cancer vaccines; Conjugate vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer
- Phase II Fallopian tube cancer; Neuroblastoma; Ovarian cancer; Peritoneal cancer
- Discontinued Prostate cancer
Most Recent Events
- 21 Sep 2023 Phase-II clinical trials in Neuroblastoma (Combination therapy, In children, In adults, In the elderly) in USA (SC) (NCT06057948)
- 01 Jul 2022 OBI Pharma plans a phase II trial for non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in June 2022 (SC) (NCT05442060)
- 05 Apr 2021 Adagloxad simolenin is still in phase III trial for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT03562637)